EA201390617A1 - Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики - Google Patents

Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики

Info

Publication number
EA201390617A1
EA201390617A1 EA201390617A EA201390617A EA201390617A1 EA 201390617 A1 EA201390617 A1 EA 201390617A1 EA 201390617 A EA201390617 A EA 201390617A EA 201390617 A EA201390617 A EA 201390617A EA 201390617 A1 EA201390617 A1 EA 201390617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
immunodiagnostics
induction
immune tolerance
factor viii
Prior art date
Application number
EA201390617A
Other languages
English (en)
Other versions
EA034494B1 (ru
Inventor
Катарина Нора Штайнитц
Паула Мария Вильхельмина Ван Хелден
Биргит Мария Райперт
Ханс-Петер Шварц
Хартмут Эрлих
Original Assignee
Бакстер Интернэшнл Инк.
Бакстер Хелткэр С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бакстер Интернэшнл Инк., Бакстер Хелткэр С.А. filed Critical Бакстер Интернэшнл Инк.
Publication of EA201390617A1 publication Critical patent/EA201390617A1/ru
Publication of EA034494B1 publication Critical patent/EA034494B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Изобретение относится к пептидам, которые можно использовать для снижения иммунного ответа против FVIII или для индукции толерантности к человеческому FVIII, у пациентов, например, с гемофилией А. Кроме того, указанные пептиды можно использовать в целях иммунодиагностики для обнаружения FVIII-специфических CD4Т-клеток для мониторинга пациентов с гемофилией А во время заместительной терапии и во время терапии индукции иммунной толерантности.
EA201390617A 2010-10-27 2011-10-27 Пептид фактора viii для индуцирования иммунной толерантности и иммунодиагностики EA034494B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US201161502476P 2011-06-29 2011-06-29
PCT/US2011/058165 WO2012058480A1 (en) 2010-10-27 2011-10-27 Fviii peptides for immune tolerance induction and immunodiagnostics

Publications (2)

Publication Number Publication Date
EA201390617A1 true EA201390617A1 (ru) 2013-10-30
EA034494B1 EA034494B1 (ru) 2020-02-13

Family

ID=45349271

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390617A EA034494B1 (ru) 2010-10-27 2011-10-27 Пептид фактора viii для индуцирования иммунной толерантности и иммунодиагностики

Country Status (20)

Country Link
US (3) US8969524B2 (ru)
EP (2) EP2632479B1 (ru)
JP (2) JP6122780B2 (ru)
KR (2) KR102040867B1 (ru)
CN (2) CN104926947A (ru)
AR (1) AR083586A1 (ru)
AU (2) AU2011319747C1 (ru)
BR (1) BR112013010362A2 (ru)
CA (1) CA2815239C (ru)
DK (1) DK2632479T3 (ru)
EA (1) EA034494B1 (ru)
ES (2) ES2912455T3 (ru)
HK (1) HK1215442A1 (ru)
MX (1) MX347805B (ru)
NZ (2) NZ703514A (ru)
PL (2) PL3260132T3 (ru)
PT (1) PT2632479T (ru)
SG (2) SG10201600656WA (ru)
TW (3) TWI580430B (ru)
WO (1) WO2012058480A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
LT2917232T (lt) * 2012-11-12 2017-06-26 Apitope International Nv Iš faktoriaus vii kilę peptidai, skirti naudoti hemofilijos gydymui
BR112015013311A2 (pt) 2012-12-07 2017-11-14 Haplomics Inc indução de tolerancia e reparação de mutação do fator 8
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
EP3154639B1 (en) * 2014-06-12 2020-09-02 University Of Hawaii Uses of humanized cobra venom factor for reducing or preventing immunogenicity
EP3250605A1 (en) * 2015-01-26 2017-12-06 Cellectis Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
MX2018012612A (es) 2016-04-15 2019-02-21 Baxalta Inc Metodo y aparato para proporcionar un regimen de dosificacion de farmacos farmacocinetica.
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0308860A (pt) 2002-04-18 2005-01-04 Merck Patent Gmbh Fator viii modificado
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US20060141528A1 (en) * 2004-05-21 2006-06-29 Aebersold Rudolf H Compositions and methods for quantification of serum glycoproteins
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations

Also Published As

Publication number Publication date
AU2016202155B2 (en) 2018-02-01
US9512198B2 (en) 2016-12-06
AU2011319747C1 (en) 2016-07-14
WO2012058480A1 (en) 2012-05-03
EP3260132B1 (en) 2022-02-09
TW201730205A (zh) 2017-09-01
ES2912455T3 (es) 2022-05-26
EA034494B1 (ru) 2020-02-13
MX2013004753A (es) 2013-09-13
EP2632479B1 (en) 2017-06-14
TW201708251A (zh) 2017-03-01
CN104926947A (zh) 2015-09-23
TW201231065A (en) 2012-08-01
AU2011319747B2 (en) 2016-01-07
US20120135019A1 (en) 2012-05-31
PT2632479T (pt) 2017-07-24
US20150203567A1 (en) 2015-07-23
US8969524B2 (en) 2015-03-03
ES2639039T3 (es) 2017-10-25
KR20190126189A (ko) 2019-11-08
CN103298482A (zh) 2013-09-11
DK2632479T3 (en) 2017-08-07
EP2632479A1 (en) 2013-09-04
CA2815239A1 (en) 2012-05-03
CN103298482B (zh) 2015-08-19
SG189914A1 (en) 2013-06-28
EP3260132A1 (en) 2017-12-27
AU2011319747A1 (en) 2013-05-02
NZ703514A (en) 2017-02-24
NZ609474A (en) 2015-06-26
PL3260132T3 (pl) 2022-08-08
KR102222864B1 (ko) 2021-03-04
HK1215442A1 (zh) 2016-08-26
US20170267743A1 (en) 2017-09-21
CA2815239C (en) 2019-02-26
AU2016202155A1 (en) 2016-04-28
AR083586A1 (es) 2013-03-06
JP2017095463A (ja) 2017-06-01
PL2632479T3 (pl) 2017-09-29
SG10201600656WA (en) 2016-02-26
MX347805B (es) 2017-05-15
JP6122780B2 (ja) 2017-04-26
KR102040867B1 (ko) 2019-11-07
JP2014505014A (ja) 2014-02-27
BR112013010362A2 (pt) 2016-08-02
TWI580430B (zh) 2017-05-01
KR20130128404A (ko) 2013-11-26

Similar Documents

Publication Publication Date Title
EA201390617A1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
CY1123404T1 (el) Αντι-girt αντισωματα
CY1124495T1 (el) Θεραπεια της amd με χρηση aav sflt-1
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
EA201590011A1 (ru) Пептидные аналоги эксендина-4
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2013002207A (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
IN2012DN06309A (ru)
CL2013000594A1 (es) Composicion que comprende hidrolizado de proteina en base lactea que proviene del tratamiento de una solucion de un material proteinaceo de base lactea con al menos una endopeptidasa tipo tripsina, y una endopeptidasa tipo quimotripsina; uso de dicha composicion como fórmula infantil o complemento alimenticio para inducción de tolerancia oral en infantes o pacientes que lo necesitan, o para reducir el riesgo de alergias.
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EA201691314A1 (ru) Терапевтические способы и композиции
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
NZ602380A (en) Peptides for vaccine against birch allergy
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
CY1123049T1 (el) Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο για χρηση σε ανθρωπους
TR201901846T4 (tr) Aşı terapisi.
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment